{
  "brand_name": "Irbesartan",
  "mission_vision": "To provide effective treatment for high blood pressure, heart failure, and diabetic kidney disease.",
  "sponsorship_activities": [],
  "channels": [
    {
      "channel_type": "Pharmaceutical Distribution",
      "specifics": [
        "Retail Pharmacies",
        "Hospitals",
        "Online Pharmacies"
      ]
    }
  ],
  "industry": {
    "Primary_Industry": "Pharmaceuticals",
    "Secondary_Industry": "Healthcare"
  },
  "regions": [
    "North America",
    "Europe",
    "Australia"
  ],
  "interests": [
    {
      "category": "Health and Wellness",
      "specifics": [
        "Alternative Medicine",
        "Holistic Health"
      ]
    }
  ],
  "audience_lifestyle": [
    "Health-conscious",
    "Patients with chronic conditions"
  ],
  "languages": [
    "English",
    "Spanish"
  ],
  "business_model_canvas": {
    "Key_Partners": [
      "Sanofi-Aventis",
      "Bristol-Myers Squibb"
    ],
    "Key_Activities": [
      "Research and Development",
      "Marketing",
      "Distribution"
    ],
    "Value_Propositions": [
      "Effective treatment for hypertension",
      "Improvement in kidney health"
    ],
    "Customer_Relationships": [
      "Patient Education Programs",
      "Healthcare Provider Engagement"
    ],
    "Customer_Segments": [
      "Patients with hypertension",
      "Patients with heart failure",
      "Patients with diabetic kidney disease"
    ],
    "Channels": [
      "Direct Sales",
      "Online Sales"
    ],
    "Cost_Structure": [
      "Research and Development Costs",
      "Marketing Expenses",
      "Manufacturing Costs"
    ],
    "Revenue_Streams": [
      "Prescription Sales",
      "Over-the-counter Sales"
    ]
  },
  "link": "https://en.wikipedia.org/wiki/Irbesartan",
  "parsed_at": "2024-10-01T14:39:00.394299Z",
  "country": "French brands",
  "category": "Sanofi",
  "body_text": "From Wikipedia, the free encyclopedia Chemical compound Irbesartan Clinical data Pronunciation / ɜːr b ə ˈ s ɑːr t ən / Trade names Aprovel, Avapro, others AHFS / Drugs.com Monograph MedlinePlus a698009 License data US DailyMed : Irbesartan Pregnancy category AU : D [ 1 ] Routes of administration By mouth Drug class Cardiovascular agent ATC code C09CA04 ( WHO ) C09DA04 ( WHO ) Legal status Legal status AU : S4 (Prescription only) [ 3 ] UK : POM (Prescription only) US : WARNING [ 2 ] Rx-only EU : Rx-only [ 4 ] In general: ℞ (Prescription only) Pharmacokinetic data Bioavailability 60% to 80% Protein binding ~90% Metabolism Liver ( CYP2C9 ) Elimination half-life 11 h to 15 h Excretion Kidney 20%, feces 65% Identifiers IUPAC name 2-butyl-3-({4-[2-(2 H -1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one CAS Number 138402-11-6 Y PubChem CID 3749 IUPHAR/BPS 589 DrugBank DB01029 Y ChemSpider 3618 Y UNII J0E2756Z7N KEGG D00523 Y ChEBI CHEBI:5959 Y ChEMBL ChEMBL1513 Y CompTox Dashboard ( EPA ) DTXSID0023169 ECHA InfoCard 100.119.966 Chemical and physical data Formula C 25 H 28 N 6 O Molar mass 428.540 g·mol −1 3D model ( JSmol ) Interactive image SMILES O=C1N(\\C(=N/C12CCCC2)CCCC)Cc5ccc(c3ccccc3c4n[nH]nn4)cc5 InChI InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30) Y Key:YOSHYTLCDANDAN-UHFFFAOYSA-N Y (verify) Irbesartan , sold under the brand name Aprovel among others, is a medication used to treat high blood pressure , heart failure , and diabetic kidney disease . [ 5 ] It is a reasonable initial treatment for high blood pressure. [ 5 ] It is taken by mouth . [ 5 ] Versions are available as the combination irbesartan/ hydrochlorothiazide . [ 5 ] [ 6 ] [ 7 ] [ 8 ] Common side effects include dizziness, diarrhea, feeling tired, muscle pain , and heartburn. [ 5 ] [ 9 ] Serious side effects may include kidney problems , low blood pressure , and angioedema . [ 5 ] Use in pregnancy may harm the baby and use when breastfeeding is not recommended. [ 10 ] It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II . [ 5 ] Irbesartan was patented in 1990, and approved for medical use in 1997. [ 11 ] It is available as a generic medication . [ 9 ] In 2021, it was the 172nd most commonly prescribed medication in the United States, with more than 3 million prescriptions. [ 12 ] [ 13 ] Medical uses [ edit ] Irbesartan is used for the treatment of hypertension. It may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, [ 14 ] hypertension and microalbuminuria (>30 mg/24 h) or proteinuria (>900 mg/24 h). [ 15 ] Combination with diuretic [ edit ] Irbesartan is also available in a fixed-dose combination formulation with hydrochlorothiazide , a thiazide diuretic , to achieve an additive antihypertensive effect. [ 16 ] [ 17 ] [ 7 ] [ 18 ] Society and culture [ edit ] Brand names [ edit ] It was developed by Sanofi Research (part of Sanofi-Aventis ). It is jointly marketed by Sanofi-Aventis and Bristol-Myers Squibb under the brand names Aprovel, Karvea, and Avapro. [ 6 ] [ 1 ] Recalls [ edit ] See also: Valsartan § recalls , and Angiotensin II receptor blocker § recalls In 2018, the US Food and Drug Administration (FDA) reported that some versions of the angiotensin II receptor blocker medicines (including valsartan , losartan , irbesartan and other \"-sartan\" drugs) contain nitrosamine impurities. [ 19 ] Health Canada also reported nitrosamine impurities. [ 20 ] The FDA issued revised guidelines about nitrosamine impurities in September 2024. [ 21 ] Retrieved from \" https://en.wikipedia.org/w/index.php?title=Irbesartan&oldid=1244285824 \" Categories : Angiotensin II receptor antagonists Sanofi Drugs developed by Bristol Myers Squibb Tetrazoles Biphenyls Lactams Spiro compounds Nitrogen heterocycles Hidden categories: Articles with short description Short description matches Wikidata Use dmy dates from June 2024 Drugs with non-standard legal status ECHA InfoCard ID from Wikidata Drugboxes which contain changes to watched fields Wikipedia medicine articles ready to translate",
  "infobox": {
    "logo_url": "https://upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Irbesartan_skeletal.svg/220px-Irbesartan_skeletal.svg.png",
    "name": "IUPAC name 2-butyl-3-({4-[2-(2 H -1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one",
    "pronunciation": "/ ɜːr b ə ˈ s ɑːr t ən /",
    "trade_names": "Aprovel, Avapro, others",
    "ahfs_drugs_com": "Monograph",
    "medlineplus": "a698009",
    "license_data": "US DailyMed : Irbesartan",
    "pregnancy_category": "AU : D [ 1 ]",
    "routes_of_administration": "By mouth",
    "drug_class": "Cardiovascular agent",
    "atc_code": "C09CA04 ( WHO ) C09DA04 ( WHO )",
    "legal_status": "AU : S4 (Prescription only) [ 3 ] UK : POM (Prescription only) US : WARNING [ 2 ] Rx-only EU : Rx-only [ 4 ] In general: ℞ (Prescription only)",
    "bioavailability": "60% to 80%",
    "protein_binding": "~90%",
    "metabolism": "Liver ( CYP2C9 )",
    "elimination_half_life": "11 h to 15 h",
    "excretion": "Kidney 20%, feces 65%",
    "cas_number": "138402-11-6 Y",
    "pubchem_cid": "3749",
    "iuphar_bps": "589",
    "drugbank": "DB01029 Y",
    "chemspider": "3618 Y",
    "unii": "J0E2756Z7N",
    "kegg": "D00523 Y",
    "chebi": "CHEBI:5959 Y",
    "chembl": "ChEMBL1513 Y",
    "comptox_dashboard_epa": "DTXSID0023169",
    "echa_infocard": "100.119.966",
    "formula": "C 25 H 28 N 6 O",
    "molar_mass": "428.540 g·mol −1",
    "3d_model_jsmol": "Interactive image"
  },
  "company_name": "IUPAC name 2-butyl-3-({4-[2-(2 H -1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one",
  "logo_url": "https://upload.wikimedia.org/wikipedia/commons/thumb/b/bb/Irbesartan_skeletal.svg/220px-Irbesartan_skeletal.svg.png"
}